Abstract

Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By 21 May 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.

中文翻译：

---

体液和细胞免疫以及 COVID-19 疫苗的安全性：2021 年 5 月 21 日发布的数据摘要

摘要

2019 年冠状病毒病 (COVID-19) 已造成数百万人死亡，并对公共卫生、经济和社会造成严重后果。自从分离出严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 并发布病毒基因组序列以来，疫苗开发方面发生了快速反应。截至2021年5月21日，已有101种疫苗正在进行临床试验，其中18种已公布数据。一些疫苗的临床研究结果表明具有良好的免疫原性和可接受的反应原性。在此，我们重点关注这18种已发表临床数据的疫苗，剖析其诱导的体液和细胞免疫反应及其安全性和保护功效。